Skip to main content
. 2006 Jul;26(13):5180–5189. doi: 10.1128/MCB.00966-05

TABLE 1.

Summary of data from FACS analysis measurements performed in this studya<

Expt. no. Date (mo-day-yr) Mouse and/or genotype Organ Culture time (h) Treatmentb Apoptotic fraction (%) Viable fraction (%) Necrotic fraction (%) Note
1 8-15-03 129 +/+ Spleen 48 Spontaneous 11.33 4.4 84.26
48 TNF-α 13.21 0.47 85.97
48 IFN-γ 10.12 0.4 89.13
48 Anti-FAS 9.96 0.41 89.3
FAT10ko −/− Spleen 48 Spontaneous 22.34 4.04 73.63
48 TNF-α 23.09 2.2 74.4
48 IFN-γ 16.7 1.2 81.74
48 Anti-FAS 18.1 1.28 80.44
2 129 +/+ Bone marrow 48 Spontaneous 34.8 2.95 62.7
48 TNF-α 30.24 1.6 67.53
48 IFN-γ 28.92 1.35 69.2
48 Anti-FAS 36.42 0.65 62.6
FAT10ko −/− Bone marrow 48 Spontaneous 49.1 1.66 49.23
48 TNF-α 37.65 0.57 61.44
48 IFN-γ 38.75 0.67 60.14
48 Anti-FAS 39.29 0.42 59.94
3 129 +/+ Thymus 48 Spontaneous 11.55 3.08 85.36
48 TNF-α 9.93 1.57 88.37
48 IFN-γ 10.125 2.77 86.43
48 Anti-FAS 8.6 1.45 89.64
FAT10ko −/− Thymus 48 Spontaneous 23.98 3.33 72.7
48 TNF-α 19.53 1.06 79.28
48 IFN-γ 20.17 1.13 78.41
48 Anti-FAS 17.14 1.3 81.15
4 9-5-03 129 +/+ Spleen 18 Spontaneous 25.2 20.06 32.1 Flow cyto problems
18 TNF-α 5.37 48.8 41.66 Flow cyto problems
18 IFN-γ 4.46 55.77 38.46 Flow cyto problems
18 Anti-FAS 9.65 39.69 46.9 Flow cyto problems
FAT10ko −/− Spleen 18 Spontaneous 21.6 24.51 34.6 Flow cyto problems
18 TNF-α 9.33 55.56 26.6 Flow cyto problems
18 IFN-γ 13.68 37.2 47.6 Flow cyto problems
18 Anti-FAS 18.95 31.85 38.4 Flow cyto problems
5 129 +/+ Spleen 18 Cycloheximide 23.25 16.33 46.2 Flow cyto problems
18 TNF-α + cycloheximide 7.65 12.83 68.99 Flow cyto problems
18 IFN-γ + cycloheximide 5.15 57.28 36.45 Flow cyto problems
18 Anti-FAS + cycloheximide 12 14.13 71.52 Flow cyto problems
FAT10ko −/− Spleen 18 Cycloheximide 14.7 18.25 51 Flow cyto problems
18 TNF-α + cycloheximide 12.35 8.25 51.96 Flow cyto problems
18 IFN-γ + cycloheximide 13.1 12.15 61.58 Flow cyto problems
18 Anti-FAS + cycloheximide 7.54 18.76 65.75 Flow cyto problems
6 9-10-03 129 +/+ Spleen 18 Spontaneous 5.37 48.79 45.84
FAT10ko −/− Spleen 18 Spontaneous 9.33 55.56 35
7 129 +/+ Spleen 18 Cycloheximide 7.65 12.83 79.5
FAT10ko −/− Spleen 18 Cycloheximide 13.1 12.15 74.6
8 9-18-03 129 +/+ Thymus 48 Spontaneous 4.46 55.77 39.77
FAT10ko −/− Thymus 48 Spontaneous 5.15 57.28 37.67
9 129 +/+ Spleen 48 Spontaneous 9.65 39.69 50.66
FAT10ko −/− Spleen 48 Spontaneous 13.68 37.19 49.1
10 129 +/+ Spleen 48 Cycloheximide 12.01 14.13 73.87
FAT10ko −/− Spleen 48 Cycloheximide 17.39 13.34 69.27
11 2-13-04 FAT10 +/+ Spleen 48 Spontaneous 11.79 13.66 74.55
FAT10ko −/− Spleen 48 Spontaneous 6.28 10.67 83
12 3-5-04 C57BL/6 +/+ Spleen 45 Spontaneous 5.52 25.74 66.7
129 +/+ Spleen 45 Spontaneous 5.27 27.02 65.7
FAT10ko −/− Spleen 45 Spontaneous 10.78 26.31 62.9
a

Values shown in boldface type were used for the final statistical analysis. Spontaneous cultures were not stimulated during incubation.

b

The following concentrations were used: 100 ng/ml of either TNF-α or IFN-γ; 1 μg/ml of anti-Fas antibody; 1 μg/ml cycloheximide.